<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35384023</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2265</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Clinical endocrinology</Title>
          <ISOAbbreviation>Clin Endocrinol (Oxf)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Relationship between growth hormone deficiency and nonalcoholic fatty liver disease in patients with pituitary stalk interruption syndrome.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cen.14732</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pituitary stalk interruption syndrome (PSIS), characterized by thinning or disappearance of the pituitary stalk, hypoplasia of the anterior pituitary, and an ectopic posterior pituitary, can lead to congenital combined pituitary hormone deficiency. There is a high prevalence of various metabolic disorders, including nonalcoholic fatty liver disease (NAFLD), in this population.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the characteristics of NAFLD in Chinese adult patients with PSIS and its association with growth hormone deficiency.</AbstractText>
          <AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cross-sectional study in a tertiary referral center of China.</AbstractText>
          <AbstractText Label="PATIENTS" NlmCategory="METHODS">Adult patients with PSIS diagnosed, followed up between September 2019 and August 2021, were consecutively enrolled.</AbstractText>
          <AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Abdominal ultrasonography images were evaluated and noninvasive fibrosis scores were determined to assess the severity of NAFLD. Anthropometric, clinical, and biochemical parameters were compared between patients with and without NAFLD. Logistic regression was performed to assess the independent effects of insulin-like growth factor-1 (IGF-1) on NAFLD.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 93 patients (77 men, 16 women, mean age: 29.6 ± 7.1 years) were included. The prevalence of NAFLD and advanced fibrosis/cirrhosis was 50.5% and 4.3%, respectively. Insufficient hormone therapy and prominent metabolic disorders, including central obesity, dyslipidemia, insulin resistance, and metabolic syndrome, were more common in the NAFLD (+) group. After adjusting for multiple variables, IGF-1 &lt;-2 standard deviation score (SDS) was found to be associated with an increased prevalence of NAFLD (odds ratio [OR]: 4.92, 95% confidence interval [CI]: 1.21-24.55, p = .035). Per 1 SDS increase in IGF-1 was associated with a 27% lower risk of NAFLD (OR: 0.73, 95% CI: 0.52-0.97, p = .042).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NAFLD is a frequent comorbidity among Chinese adult patients with PSIS and is strongly associated with lower IGF-1 levels. Timely and appropriate hormone replacement, particularly growth hormone may contribute to decreasing the risk of NAFLD in these patients.</AbstractText>
          <CopyrightInformation>© 2022 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Qibin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Hongli</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xi</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mao</LastName>
            <ForeName>Jiangfeng</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Bingqing</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-0459-1923</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Yiyi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Bang</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Junyi</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ji</LastName>
            <ForeName>Wen</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-0871-6922</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Wanlu</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nie</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-3061-8103</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Xueyan</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0003-2540-8590</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Clin Endocrinol (Oxf)</MedlineTA>
        <NlmUniqueID>0346653</NlmUniqueID>
        <ISSNLinking>0300-0664</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">fibrosis</Keyword>
        <Keyword MajorTopicYN="N">growth hormone</Keyword>
        <Keyword MajorTopicYN="N">insulin-like growth factor-1</Keyword>
        <Keyword MajorTopicYN="N">nonalcoholic fatty liver disease</Keyword>
        <Keyword MajorTopicYN="N">pituitary stalk interruption syndrome</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>9</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35384023</ArticleId>
        <ArticleId IdType="doi">10.1111/cen.14732</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Ruissen MM, Mak AL, Beuers U, Tushuizen ME, Holleboom AG. Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease. Eur J Endocrinol. 2020;183(3):R57-R73. doi:10.1530/EJE-20-0065</Citation>
        </Reference>
        <Reference>
          <Citation>Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi:10.1002/hep.29367</Citation>
        </Reference>
        <Reference>
          <Citation>Nishizawa H, Iguchi G, Murawaki A, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol. 2012;167(1):67-74. doi:10.1530/EJE-12-0252</Citation>
        </Reference>
        <Reference>
          <Citation>Yang Y, Qi ZR, Zhang TT, Kang YJ, Wang X. Rapidly progressive non-alcoholic fatty liver disease due to hypopituitarism. Report of 5 cases. Neuro Endocrinol Lett. 2018;39(2):99-104.</Citation>
        </Reference>
        <Reference>
          <Citation>Vergier J, Castinetti F, Saveanu A, Girard N, Brue T, Reynaud R. DIAGNOSIS OF ENDOCRINE DISEASE: Pituitary stalk interruption syndrome: etiology and clinical manifestations. Eur J Endocrinol. 2019;181(5):R199-r209. doi:10.1530/eje-19-0168</Citation>
        </Reference>
        <Reference>
          <Citation>Wu ZY, Li YL, Chang B. Pituitary stalk interruption syndrome and liver changes: From clinical features to mechanisms. World J Gastroenterol. 2020;26(44):6909-6922. doi:10.3748/wjg.v26.i44.6909</Citation>
        </Reference>
        <Reference>
          <Citation>Ji W, Nie M, Mao JF, Zhang HB, Wang X, Wu XY. Growth hormone cocktail improves hepatopulmonary syndrome secondary to hypopituitarism: a case report. World J Clin Cases. 2021;9(18):4852-4858. doi:10.12998/wjcc.v9.i18.4852</Citation>
        </Reference>
        <Reference>
          <Citation>Zheng J, Mao J, Xu H, et al. Pulsatile GnRH therapy may restore hypothalamus-pituitary-testis axis function in patients with congenital combined pituitary hormone deficiency: a prospective, self-controlled trial. J Clin Endocrinol Metab. 2017;102(7):2291-2300. doi:10.1210/jc.2016-3990</Citation>
        </Reference>
        <Reference>
          <Citation>Yuen KCJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019;25(11):1191-1232. doi:10.4158/gl-2019-0405</Citation>
        </Reference>
        <Reference>
          <Citation>Alberti C, Chevenne D, Mercat I, et al. Serum concentrations of insulin-like growth factor (IGF)-1 and IGF binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio, and markers of bone turnover: reference values for French children and adolescents and z-score comparability with other references. Clin Chem. 2011;57(10):1424-1435. doi:10.1373/clinchem.2011.169466</Citation>
        </Reference>
        <Reference>
          <Citation>Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325. doi:10.1002/hep.21178</Citation>
        </Reference>
        <Reference>
          <Citation>Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-854. doi:10.1002/hep.21496</Citation>
        </Reference>
        <Reference>
          <Citation>Lu J, Wang L, Li M, et al. Metabolic syndrome among adults in China: The 2010 China noncommunicable disease surveillance. J Clin Endocrinol Metab. 2017;102(2):507-515. doi:10.1210/jc.2016-2477</Citation>
        </Reference>
        <Reference>
          <Citation>Salgado AL, Carvalho L, Oliveira AC, Santos VN, Vieira JG, Parise ER. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010;47(2):165-169. doi:10.1590/s0004-28032010000200009</Citation>
        </Reference>
        <Reference>
          <Citation>Yuan XX, Zhu HJ, Pan H, et al. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients. World J Gastroenterol. 2019;25(14):1741-1752. doi:10.3748/wjg.v25.i14.1741</Citation>
        </Reference>
        <Reference>
          <Citation>Hong JW, Kim JY, Kim YE, Lee EJ. Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men. Horm Metab Res. 2011;43(1):48-54. doi:10.1055/s-0030-1265217</Citation>
        </Reference>
        <Reference>
          <Citation>Kang SJ, Kwon A, Jung MK, et al. High prevalence of nonalcoholic fatty liver disease among adolescents and young adults with hypopituitarism due to growth hormone Deficiency. Endocr Pract. 2021;27:1149-1155. doi:10.1016/j.eprac.2021.06.003</Citation>
        </Reference>
        <Reference>
          <Citation>Barclay JL, Nelson CN, Ishikawa M, et al. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology. 2011;152(1):181-192. doi:10.1210/en.2010-0537</Citation>
        </Reference>
        <Reference>
          <Citation>Grohmann M, Wiede F, Dodd GT, et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell. 2018;175(5):1289-1306 e1220. doi:10.1016/j.cell.2018.09.053</Citation>
        </Reference>
        <Reference>
          <Citation>Cui Y, Hosui A, Sun R, et al. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology. 2007;46(2):504-513. doi:10.1002/hep.21713</Citation>
        </Reference>
        <Reference>
          <Citation>Nishizawa H, Takahashi M, Fukuoka H, Iguchi G, Kitazawa R, Takahashi Y. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. Biochem Biophys Res Commun. 2012;423(2):295-300. doi:10.1016/j.bbrc.2012.05.115</Citation>
        </Reference>
        <Reference>
          <Citation>Nishizawa H, Iguchi G, Fukuoka H, et al. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner. Sci Rep. 2016;6:34605. doi:10.1038/srep34605</Citation>
        </Reference>
        <Reference>
          <Citation>Hribal ML, Procopio T, Petta S, et al. Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2013;98(2):E304-E308. doi:10.1210/jc.2012-3290</Citation>
        </Reference>
        <Reference>
          <Citation>Yao Y, Miao X, Zhu D, et al. Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis. Endocrine. 2019;65(2):227-237. doi:10.1007/s12020-019-01982-1</Citation>
        </Reference>
        <Reference>
          <Citation>Carvalho-Furtado ACL, Carvalho-Louro DM, Regattieri NAT, et al. Transient elastography and controlled attenuation parameter (CAP) in the assessment of liver steatosis in severe adult growth hormone deficiency. Front Endocrinol (Lausanne). 2019;10:364. doi:10.3389/fendo.2019.00364</Citation>
        </Reference>
        <Reference>
          <Citation>Meienberg F, Yee M, Johnston D, et al. Liver fat in adults with GH deficiency: comparison to matched controls and the effect of GH replacement. Clin Endocrinol (Oxf). 2016;85(1):76-84. doi:10.1111/cen.13042</Citation>
        </Reference>
        <Reference>
          <Citation>Auer MK, Stalla GK, Stieg MR. Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas. Pituitary. 2016;19(5):461-471. doi:10.1007/s11102-016-0726-1</Citation>
        </Reference>
        <Reference>
          <Citation>Yim JY, Kim J, Kim D, Ahmed A. Serum testosterone and non-alcoholic fatty liver disease in men and women in the US. Liver Int. 2018;38(11):2051-2059. doi:10.1111/liv.13735</Citation>
        </Reference>
        <Reference>
          <Citation>Kim S, Kwon H, Park JH, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol. 2012;12:69. doi:10.1186/1471-230x-12-69</Citation>
        </Reference>
        <Reference>
          <Citation>Xiao J, Zhu C, Zhang X, et al. Associations among FT4 level, FT3/FT4 ratio, and non-alcoholic fatty liver disease in Chinese patients with hypopituitarism. Endocr J. 2022. doi:10.1507/endocrj.EJ21-0536</Citation>
        </Reference>
        <Reference>
          <Citation>Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. doi:10.1038/nrgastro.2017.109</Citation>
        </Reference>
        <Reference>
          <Citation>Gonzalez Rozas M, Hernanz Roman L, Gonzalez DG, Pérez-Castrillón JL. Panhypopituitarism due to absence of the pituitary stalk: a rare aetiology of liver cirrhosis. Case Rep Endocrinol. 2016;2016:9071097. doi:10.1155/2016/9071097</Citation>
        </Reference>
        <Reference>
          <Citation>Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13:321-350. doi:10.1146/annurev-pathol-020117-043617</Citation>
        </Reference>
        <Reference>
          <Citation>Miljić D, Popovic V. Metabolic Syndrome in Hypopituitarism. Front Horm Res. 2018;49:1-19. doi:10.1159/000485997</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
